Ozempic plus metformin for PCOS and type 2 diabetes: what week 12 results actually mean

What did @jennileephotos actually say?

She reported losing 25 pounds over 12 weeks on semaglutide (Ozempic) combined with metformin, with 15 pounds lost beforehand through lifestyle changes, for a total of 40 pounds. She mentioned PCOS and type 2 diabetes context, has upcoming bloodwork, and is now under 200 pounds for the first time in 15 years.

To be precise about her framing: she said she had started losing weight before Ozempic and is careful to separate her pre-medication losses from her on-medication losses. That kind of transparency is genuinely rare in weight loss content. She did not attribute all 40 pounds to the drug, which matters.

She also does not give dosing information, does not recommend anyone start Ozempic, and frames her results as personal. That is a responsible approach for a platform where health misinformation spreads fast.

Does the science back this up?

Roughly, yes. A rate of about 2 pounds per week over 12 weeks on semaglutide is on the higher end of typical but not outside what trials document, especially early in treatment when appetite suppression is most pronounced.

The SUSTAIN and STEP trial series are the reference points here. In STEP 1 (Wilding et al., 2021, New England Journal of Medicine), participants on 2.4mg semaglutide lost an average of 14.9 percent of body weight over 68 weeks. Early-phase losses in the first 12 weeks tend to be steeper than the overall average, so 25 pounds from a starting weight above 200 pounds is plausible. That said, individual variation is wide. Metformin alone is not a meaningful weight loss drug for most people, though it may modestly support insulin sensitivity in PCOS, which can indirectly reduce fat storage driven by hyperinsulinemia (Naderpoor et al., 2015, Human Reproduction Update).

What did they get wrong (or right)?

Mostly right, with one area worth flagging. She got the separation of losses correct, the clinical oversight correct (she mentions bloodwork and a follow-up appointment), and her emotional framing is honest rather than promotional.

The one thing that deserves scrutiny is the implicit suggestion that crossing into the "overweight" BMI category from "obese" is a clear clinical milestone. BMI is a blunt instrument. For someone with PCOS, metabolic markers like fasting insulin, A1C, and triglycerides tell a more useful story than the number on a scale or a BMI cutoff. Her doctor visit will matter more than the 12-pound BMI threshold she is targeting. That is not a criticism of her goal, just context she did not provide. She is also on a combination regimen, and the relative contribution of each drug to her results is genuinely unknowable from this video.

What should you actually know?

If you have PCOS and type 2 diabetes and are considering semaglutide, the evidence base is real but the details are in the fine print. Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), which are different indications at different doses. Metformin is a first-line type 2 diabetes drug and is commonly used off-label for PCOS-related insulin resistance.

What the trials do not capture well is the combination effect. There is limited high-quality data on semaglutide plus metformin specifically in PCOS populations. The PCOS evidence for GLP-1 receptor agonists is growing but still early (Jensterle et al., 2022, Diabetes, Obesity and Metabolism found liraglutide superior to metformin alone for weight in PCOS, but semaglutide-specific PCOS RCT data remains thin).

Results like hers are possible. They are not guaranteed. And the regain data after stopping semaglutide is sobering: Wilding et al. (2022, Diabetes, Obesity and Metabolism) documented roughly two-thirds of lost weight regained within one year of stopping. That context belongs in every weight loss success video.

Bottom line

This is one of the more responsibly presented weight loss updates you will find on TikTok. She credits her doctor, mentions bloodwork, separates pre-drug from on-drug results, and does not tell anyone to do what she is doing. The 25-pound loss in 12 weeks is aggressive but biologically plausible. The science on semaglutide is solid. The science on long-term outcomes and what happens after you stop is less cheerful, and that part rarely makes it into the week 12 update.